Summary:
We are seeking participants for a Type 2 Diabetic clinical research study to demonstrate whether switching from a stable dose of a Glucagon-like peptide-1 receptor agonists (GLP-1 RA) (Victoza, Saxenda, Trulicity, Ozempic) to Tirzepatide 5 mg once weekly will help lower HbA1c.
Qualified Participants Must:
• 18 years of age or older
• Have a diagnosis of type 2 diabetes
• Have an HbA1c value of ≥6.5% (≥ 48 mmol/mol) to ≤ 9.0%
• Body Mass Index (BMI) ≤ 25 kg/m²
• Additional qualification criteria exist
Qualified Participants May Receive:
- Reimbursement available for time and travel
- You are provided study-related care and study medicine at no cost (no health insurance required)